Enhancing the Prognostic Value of Cardiac Imaging With Multimodal Risk Assessment⁎⁎Editorials published in JACC: Cardiovascular Imaging reflect the views of the authors and do not necessarily represent the views of JACC: Cardiovascular Imaging or the American College of Cardiology.  by Tang, W.H. Wilson
J A C C : C A R D I O V A S C U L A R I M A G I N G V O L . 2 , N O . 9 , 2 0 0 9
© 2 0 0 9 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 1 9 3 6 - 8 7 8 X / 0 9 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . D O I : 1 0 . 1 0 1 6 / j . j c m g . 2 0 0 9 . 0 7 . 0 0 2E D I T O R I A L C O M M E N T
Enhancing the Prognostic Value of Cardiac Imaging
With Multimodal Risk Assessment*
W. H. Wilson Tang, MD
Cleveland, OhioProgress in multimodality cardiac imaging has re-
lied upon technological advances in providing better
accuracy and quantification of the images of inter-
est. Newer-generation cardiovascular diagnostic
imaging tools are already equipped with unsur-
passed capabilities to integrate a wide range of
imaging constructs. This allows the generation of
superior characterization of cardiovascular pathol-
ogy, with the promise to better guide the clinician
in deciding the best care for their patients. Al-
though the debate has surrounded which imaging
See page 1093
modality (or combination thereof ) might provide
the best prediction or reclassification of cardiovas-
cular risk, the majority of proposals using existing
imaging modalities are still confined to the visual
characterization of the cardiovascular structure or
function. This is particularly challenging under
screening conditions when the lack of clinical man-
ifestations might limit the ability to conduct clinical
correlation with the imaging findings.
Several noninvasive strategies have evolved over
the years with the hope of better defining future
risks of subclinical diseases. Coronary artery cal-
cium (CAC) score is one of more extensively studied
screening modalities, providing an integrated quan-
titative estimate of the degree of atherosclerotic
plaque that has progressed to calcification. At
present, CAC score is relatively well-accepted in
clinical practice as a surrogate for plaque burden,
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women (1), and has been consistently demonstrated
to provide important prognostic value (2). Recent
analyses have also confirmed that higher CAC
scores might allow reclassification of asymptomatic
patients from intermediate- to high-risk categories
in up to one-quarter of patients (3). However, the
requirement for radiation exposure is an unavoid-
able limitation for population screening. Questions
have also been raised as to whether the presence of
calcified plaques correlates with the same culprit
lesions that lead to subsequent adverse cardiac
events (4). In addition, the presence of calcified
plaques might limit the reversal potential of athero-
sclerotic burden (5), and serial measurements might
not directly correlate with treatment responses or
outcomes (6,7). Also, CAC score screening did not
confer any incremental benefits to treatment guided
by stress perfusion imaging (8). Hence, how to best
characterize atherosclerosis disease progression
once calcified plaques have been identified (i.e.,
with an intermediate or high CAC score) remains
to be determined.
Over the years, there has been an extensive search
for ways to characterize vulnerable plaque, particu-
larly related to cell and blood markers of the
inflammatory process (9). Myeloperoxidase (MPO)
is a leukocyte-derived enzyme that catalyzes the
formation of a number of reactive oxidant species
and negatively impacts regional nitric oxide levels,
leading to increased plaque vulnerability and the
development of cardiovascular events (10). Logi-
cally, the presence of atherosclerotic plaque should
enhance the ability of MPO to provide prognostic
value, because MPO itself seems to contribute to
processes involved in plaque rupture and intracoro-
nary thrombus generation (11). Being a simple
blood test that can be widely available in any
standard clinical laboratory, MPO testing might
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1101rovide the versatility and the potential clinical
tility in serial monitoring of disease progression.
lasma MPO levels show the greatest prognostic
alue among subjects presenting with a history of
hest discomfort or suspect acute coronary syn-
romes (12–14), and use in risk stratification of
igher-risk subjects is the indication for which
PO in vitro diagnostic testing received Food and
rug Administration clearance. However, com-
ercial assays only quantify circulating MPO mass
ather than MPO activity in leukocytes, and pre-
nalytical specimen handling and processing are
ritical to producing accurate results (15). Although
ome studies have suggested that asymptomatic
atients might have similar plasma MPO levels
egardless of whether they had underlying coronary
rtery disease (16), a recent large case control study
erived from the EPIC/Norfolk (European Pro-
pective Investigation Into Cancer in Norfolk Pro-
pective Population Study) cohort, a community-
ased screen of over 25,000 subjects, demonstrated
hat elevated systemic levels of MPO was associated
ith increased risk for development of coronary
rtery disease and mortality risk (17).
It is in the context of combining cardiovascular
maging with a biomarker linked to the pathophys-
ology of vulnerable plaque that Wong et al. (18)
ooked beyond traditional imaging techniques. In
his issue of iJACC, they report results of a multi-
odal approach at risk stratification examining the
linical utility of combining the detection of ath-
rosclerotic plaque (indicated by elevated CAC
cores) with a marker of the pathogenic process of
laque vulnerability (elevated plasma MPO levels).
n a study of over 1,300 individuals, they observed
hat, compared with those with low CAC scores (0
o 9), those with high CAC score (100) had a
9.5-fold risk increase in adverse cardiac events
hen also presenting with high plasmaMPO levels,
ven after adjusting for clinical covariates. In other
ords, elevated CAC score clearly serves as a
owerful risk stratification tool, but once high CAC
cores are observed there is potential for dynamic
PO testing to help gauge who might be at lower
isk. Within the cohort examined, a lower plasma
PO level provided some reassurance of a lower
ate for cardiovascular events than a high plasma
PO level (7.1% vs. 14.0% at 3.8 years, respec-
ively). To look at this from another angle, for an
symptomatic patient with a detectable high plasma
PO level, a CAC score 100 might provide
ome reassurance, with cardiovascular risk equiva-
ent to that of low plasma MPO levels. Whether Cther biomarkers of plaque vulnerability can serve
imilar complementary prognostic roles will need
urther investigations (9).
These data might also provide the possibility of
nstituting more aggressive preventive measures
iming at global cardiovascular risk reduction efforts
n those with elevated CAC score and plasmaMPO
evels. Ideally, we would like to know how to elicit
owering plasma MPO levels, presumably reducing
laque vulnerability. However at present, limited
nformation is available on serial plasma MPO
easures in response to various cardiovascular
isk-reducing agents. Undoubtedly in the current
ost-conscious and risk-adverse environment, there
s a need to demonstrate effectiveness of such
echanistic-based multimodality testing in a pro-
pective manner with stringent evaluation criteria
19). This is because even the appropriateness of use
or some of the most widely used modalities can be
hallenged when prospective diagnostic algorithms
n at-risk individuals do not produce the intended
avorable results (20), and not all mechanism-based
nterventions can lead to favorable outcomes (21).
Gaining mechanistic insight as part of multimo-
ality imaging might not be a far cry from reality.
or example, MPO has become a target for func-
ional imaging of vulnerable plaque and monitoring
ascular inflammation, such as within ischemic
troke (22). Direct imaging of MPO activity via an
ctivatable magnetic probe and cardiac magnetic
esonance has also been used to monitor in real time
healing myocardial infarction of an ischemia-
erfusion animal model, providing a direct visual
emonstration of the mechanistic link between
PO expression and both the progression of vul-
erable plaque and the involvement of MPO in
dverse ventricular remodeling (23). Although the
echnology of MPO functional imaging is in its
nfancy and we still cannot adequately visualize the
ulnerable plaque, combining diagnostic MPO
esting with CAC imaging as a risk stratification
pproach seems to be an attractive and powerful
ption with immediate applicability in clinical prac-
ice. We definitely need further investigations to
efine how to best use imaging modalities in com-
ination with biomarker testing as multimodal risk
ssessment so that we might better apply preventive
easures and fulfill the promise of monitoring
hose that are vulnerable to cardiovascular events.
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